Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

A hidden immune cascade linking the gut and bone marrow may explain how IBD turns inflammation into colon cancer.

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since being founded last year, Caldera has already taken the therapy, dubbed CLD-423, ...

It can be overwhelming to receive a diagnosis of inflammatory bowel disease (IBD), a condition which refers to the chronic diseases that can cause inflammation in your gastrointestinal (GI) tract.

Although inflammatory bowel disease (IBD) starts in the gut, it doesn’t always stay there. According to a 2015 study in the journal Inflammatory Bowel Disease, up to 47% of people with IBD will ...

Single-center study finds durable, steroid-free remission, especially in ulcerative coliti ...

Inflammatory bowel disease (IBD) patients face significant health care access barriers, leading to medication rationing and adverse health outcomes. Key issues include appointment availability and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients infected with SARS-CoV-2 during the first wave ...